All In Biotech

Drug Trial Radar · NCT01264770

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: May 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 644 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

644

Actual

Start

Jan 2011

Primary completion

Oct 2012

Study completion Aug 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the improvements in signs and symptoms of rheumatoid arthritis (RA) for fostamatinib compared to placebo or adalimumab in patients who are Disease-Modifying anti-rheumatic drug (DMARD) naïve, DMARD intolerant or have had an inadequate response to DMARDs. The study will last for approximately six months

Conditions

  • Rheumatoid Arthritis

Interventions

  • Fostamatinib and placebo injectionsDrug

    Fostamatinib 100mg twice daily and placebo injection once every two weeks

  • Fostamatinib and placebo injectionsDrug

    Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks

  • Fostamatinib and placebo injectionsDrug

    Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.

  • Adalimumab and placebo of fostamatinibDrug

    Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.

  • Placebo of fostamatinib, fostamatinib, and placebo injectionsDrug

    Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DAS28-CRP Score - Change From Baseline to Week 6 Compared to PlaceboTime frame: Baseline and 6 weeks
  2. DAS28-CRP Score - Change From Baseline to Week 24 Compared to AdalimumabTime frame: Baseline and 24 weeks

Locations

105 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Huntington Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Palm Harbor, Florida

  • Research Site

    Pinellas Park, Florida

  • Research Site

    Venice, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    South Bend, Indiana

  • Research Site

    Bowling Green, Kentucky

  • Research Site

    Elizabethtown, Kentucky

  • Research Site

    Oxon Hill, Maryland

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    Richmond Heights, Missouri

  • Research Site

    Kalispell, Montana

  • Research Site

    Nashua, New Hampshire

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    Brooklyn, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Perrysburg, Ohio

  • Research Site

    Duncansville, Pennsylvania

  • Research Site

    Greenville, South Carolina

  • Research Site

    Jackson, Tennessee

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Memphis, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Mesquite, Texas

  • Research Site

    Plano, Texas

  • Research Site

    San Antonio, Texas

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.